IntelliCyt, a provider of assay screening solutions for phenotypic drug discovery, has raised an $8.373 million financing round, according to a recent filing with the SEC. The round was led by new investor Arboretum Ventures and included participation from existing investors Prolog Ventures, Verge Fund and New Mexico Community Capital. Based in Albuquerque, NM, IntelliCyt “develops high-throughput cell and bead-based screening solutions for use throughout the life sciences,” according to its website. In connection with the financing, Tim Petersen and George Dunbar of Arboretum Ventures will join the company’s Board of Directors.
